MaxCyte, Inc. (MXCT) Announces Departure of Chief Commercial Officer

On August 11, 2025, Ali Soleymannezhad’s employment as Chief Commercial Officer of MaxCyte, Inc. (NASDAQ: MXCT), ended. Mr. Soleymannezhad, in accordance with the terms of his Amended and Restated Severance Agreement dated July 1, 2024, (the “Severance Agreement”), will receive (i) his base salary for a period of nine months following the date of his termination (the “Severance Period”), and (ii) contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act for the Severance Period. Mr. Soleymannezhad’s receipt of these benefits is contingent upon the execution and effectiveness of, and Mr. Soleymannezhad’s continued compliance with, the release of claims as found in the Severance Agreement. The foregoing description of the Severance Agreement is qualified by reference to the Severance Agreement, a copy of which was filed as exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Nuvectis Pharma (NVCT) files $200M mixed shelf
• Baiya International Group (BIYA) files $200M mixed shelf